BioCryst Pharma (BCRX) Misses Q4 EPS by 23c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.84 --0%
Revenue Growth %: +13.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
CRMT, PKE, More
Revenue Growth %: +13.7%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), $0.23 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $79.5 million versus the consensus estimate of $75.57 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
- JPMorgan on Tesla (TSLA): 'Strong 2Q Deliveries Beat Coincides with FSD Progress That Should Drive Positive Feedback Loops'
- S&P Global restructures Market Intelligence into two units
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
